US20050084526A1 - New process 1 - Google Patents

New process 1 Download PDF

Info

Publication number: US20050084526A1
Authority: US; United States
Prior art keywords: granulation; granules; granulation medium; tablets; medium
Prior art date: 2002-01-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

US10/501,899

Other languages

English (en)

Inventor

Jari Alander

Staffan Norberg

Henri Hansson

Marianne Svard

Lars Hovgaard

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Galenica AB

Original Assignee

Galenica AB

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-21

Filing date

2003-01-21

Publication date

2005-04-21

2003-01-21 Application filed by Galenica AB filed Critical Galenica AB

2005-01-10 Assigned to GALENCIA AB reassignment GALENCIA AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALANDER, JARI, HANSSON, HENDRI, HOVGARD, LARS, NORBERG, STAFFAN, SVARD, MARIANNE

2005-04-21 Publication of US20050084526A1 publication Critical patent/US20050084526A1/en

Status Abandoned legal-status Critical Current

Links

FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 title 1
238000005469 granulation Methods 0.000 claims abstract description 93
230000003179 granulation Effects 0.000 claims abstract description 93
239000008187 granular material Substances 0.000 claims abstract description 39
239000000203 mixture Substances 0.000 claims abstract description 36
239000004094 surface-active agent Substances 0.000 claims abstract description 30
239000000945 filler Substances 0.000 claims abstract description 25
239000007788 liquid Substances 0.000 claims abstract description 24
238000000034 method Methods 0.000 claims abstract description 24
239000000126 substance Substances 0.000 claims abstract description 15
238000002156 mixing Methods 0.000 claims abstract description 14
238000001035 drying Methods 0.000 claims abstract description 12
238000002360 preparation method Methods 0.000 claims abstract description 5
238000007873 sieving Methods 0.000 claims abstract description 4
239000004530 micro-emulsion Substances 0.000 claims description 23
239000000839 emulsion Substances 0.000 claims description 19
239000011230 binding agent Substances 0.000 claims description 16
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 7
239000012729 immediate-release (IR) formulation Substances 0.000 claims description 7
235000014113 dietary fatty acids Nutrition 0.000 claims description 6
239000000194 fatty acid Substances 0.000 claims description 6
229930195729 fatty acid Natural products 0.000 claims description 6
239000002202 Polyethylene glycol Substances 0.000 claims description 4
-1 fatty acid esters Chemical class 0.000 claims description 4
229920001223 polyethylene glycol Polymers 0.000 claims description 4
239000003826 tablet Substances 0.000 description 52
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 45
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
239000003921 oil Substances 0.000 description 26
239000013543 active substance Substances 0.000 description 17
239000012530 fluid Substances 0.000 description 17
VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 15
229920000036 polyvinylpyrrolidone Polymers 0.000 description 13
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 13
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 12
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 11
229930105110 Cyclosporin A Natural products 0.000 description 11
108010036949 Cyclosporine Proteins 0.000 description 11
229940069328 povidone Drugs 0.000 description 11
229920003084 Avicel® PH-102 Polymers 0.000 description 9
SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 8
238000004090 dissolution Methods 0.000 description 8
229940079593 drug Drugs 0.000 description 8
239000003814 drug Substances 0.000 description 8
235000019197 fats Nutrition 0.000 description 8
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 8
238000002844 melting Methods 0.000 description 8
230000008018 melting Effects 0.000 description 8
239000000843 powder Substances 0.000 description 8
238000001816 cooling Methods 0.000 description 7
239000004148 curcumin Substances 0.000 description 7
229940109262 curcumin Drugs 0.000 description 7
235000012754 curcumin Nutrition 0.000 description 7
VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 7
239000000905 isomalt Substances 0.000 description 7
235000010439 isomalt Nutrition 0.000 description 7
HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 7
238000003756 stirring Methods 0.000 description 7
238000005550 wet granulation Methods 0.000 description 7
238000013270 controlled release Methods 0.000 description 6
239000006185 dispersion Substances 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
229920000168 Microcrystalline cellulose Polymers 0.000 description 5
229920003080 Povidone K 25 Polymers 0.000 description 5
239000002775 capsule Substances 0.000 description 5
239000008101 lactose Substances 0.000 description 5
229940016286 microcrystalline cellulose Drugs 0.000 description 5
235000019813 microcrystalline cellulose Nutrition 0.000 description 5
239000008108 microcrystalline cellulose Substances 0.000 description 5
239000002245 particle Substances 0.000 description 5
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
229920000053 polysorbate 80 Polymers 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
229960000905 indomethacin Drugs 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 4
239000008188 pellet Substances 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
239000007916 tablet composition Substances 0.000 description 4
229920002560 Polyethylene Glycol 3000 Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000009826 distribution Methods 0.000 description 3
229940088679 drug related substance Drugs 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
239000004973 liquid crystal related substance Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
238000013019 agitation Methods 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
210000004051 gastric juice Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000007909 melt granulation Methods 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
241000070918 Cima Species 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000012382 advanced drug delivery Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
229920002678 cellulose Chemical class 0.000 description 1
239000001913 cellulose Chemical class 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
229940068682 chewable tablet Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
238000007599 discharging Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
239000007938 effervescent tablet Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
235000019866 hydrogenated palm kernel oil Nutrition 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000031891 intestinal absorption Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000010030 laminating Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
150000004667 medium chain fatty acids Chemical class 0.000 description 1
238000010309 melting process Methods 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
229940095352 oral pellet Drugs 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229940100487 povidone k25 Drugs 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
230000001603 reducing effect Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000004260 weight control Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Definitions

WO 99/44589 discloses an oral pellet for immediate release of an active substance, comprising at least said active substance, a binding agent and a diluting agent.
FIG. 1 shows the dissolution in phosphate buffer, pH 7.4, of tablets according to the invention containing different amounts of curcumin compared to a curcumin tablet formulation without lipid and surfactant.
the granulation medium is a microemulsion.
Microemulsions are thermodynamically stable isotropically clear solutions consisting of water, oil and surfactants. They can be characterised as o/w (oil-in-water), w/o (water-in-oil) or as bicontinuous phases. According to another terminology they are described as a micellar or a reversed micellar solution. The formation of a microemulsion requires no energy input.

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

US10/501,899 2002-01-21 2003-01-21 New process 1 Abandoned US20050084526A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
SE0200154-3		2002-01-21
SE0200154A SE0200154D0 (sv)	2002-01-21	2002-01-21	New process
PCT/SE2003/000092 WO2003061627A1 (fr)	2002-01-21	2003-01-21	Nouveau procede 1

Publications (1)

Publication Number	Publication Date
US20050084526A1 true US20050084526A1 (en)	2005-04-21

Family

ID=20286712

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
US10/501,899 Abandoned US20050084526A1 (en)	2002-01-21	2003-01-21	New process 1
US10/501,873 Expired - Lifetime US7422757B2 (en)	2002-01-21	2003-01-21	Tabletting process

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
US10/501,873 Expired - Lifetime US7422757B2 (en)	2002-01-21	2003-01-21	Tabletting process

Country Status (4)

Country	Link
US (2)	US20050084526A1 (fr)
EP (2)	EP1467708A1 (fr)
SE (1)	SE0200154D0 (fr)
WO (2)	WO2003061630A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060182799A1 (en) *	2002-01-21	2006-08-17	Jari Alander	Tabletting process
US12318425B2 (en)	2018-10-23	2025-06-03	Stabicon Life Sciences Pvt. Ltd.	Formulation comprising water soluble particles of a non-curcuminoid and a curcuminoid

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070122471A1 (en) *	2003-12-25	2007-05-31	Takeda Pharmaceutical Company Limited	Method of improving suitability for granulation
US20060099253A1 (en) *	2004-10-20	2006-05-11	Wyeth	Antibiotic product formulation
JP4722933B2 (ja) *	2005-08-31	2011-07-13	江崎グリコ株式会社	舌苔除去用タブレット
EP1905427B1 (fr)	2006-09-28	2010-11-24	Losan Pharma GmbH	Formulation solubilisée rapidement des anti-inflammatoires non stéroïdiens
JP5245175B2 (ja) *	2006-11-13	2013-07-24	杏林製薬株式会社	持続放出型錠剤の製造方法
EP2101739A2 (fr) *	2006-12-21	2009-09-23	Mallinckrodt Inc.	Comprimés à désintégration par voie orale contenant une dose élevée de principes actifs: composition utilisée et méthodes de fabrication
EP2101738A2 (fr) *	2006-12-21	2009-09-23	Mallinckrodt Inc.	Comprimés à désintégration par voie orale: composition utilisée et méthode de fabrication orale
US20110037185A1 (en) *	2008-04-30	2011-02-17	James Kowalski	Continuous process for making pharmaceutical compositions
IT1400695B1 (it) *	2010-06-21	2013-06-28	Labomar S R L	Composizioni farmaceutiche e/o nutraceutiche contenenti principi attivi insolubili in acqua e procedimento per ottenerle.
ITMI20111259A1 (it) *	2011-07-06	2013-01-07	Eye Tech Srl	Composizione orosolubile a rapida disgregazione contenente derivati di curcumina
JP6219321B2 (ja) *	2012-03-07	2017-10-25	アールト・ユニバーシティ・ファウンデイションＡａｌｔｏＵｎｉｖｅｒｓｉｔｙＦｏｕｎｄａｔｉｏｎ	飼料のエネルギー含量を増加させることにおける純セルロースの使用
CN106399102A (zh) *	2016-09-14	2017-02-15	青岛佳明测控科技股份有限公司	微生物颗粒培养基的简便制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4568547A (en) *	1979-08-30	1986-02-04	Herschler R J	Solid pharmaceutical compositions comprising MSM and their production
DE3721721C1 (de) *	1987-07-01	1988-06-09	Hoechst Ag	Verfahren zur Umhuellung von Granulaten
IE65045B1 (en)	1990-04-28	1995-10-04	Takeda Chemical Industries Ltd	Granulated preparations and method of producing the same
BE1006990A5 (nl) *	1993-04-22	1995-02-07	Univ Gent	Werkwijze en samenstelling om een aktief bestanddeel in een vaste toedieningsvorm te brengen.
FR2710535B1 (fr) *	1993-09-30	1995-11-24	Gattefosse Ets Sa	Composition à usage pharmaceutique ou cosmétique apte à former une microémulsion.
DE69633925T2 (de) *	1995-07-21	2005-11-24	Daiichi Pharmaceutical Co., Ltd.	Verfahren zur Herstellung einer granulären Zubereitung
EP0911032B2 (fr) *	1997-10-27	2004-09-01	Dr. Gergely & Co.	Compositions effervescentes contenant des extraits végétaux
EP1146856B1 (fr) *	1999-01-12	2003-07-02	Merck Sharp & Dohme Limited	Systeme auto-emulsionnant spheronise destine a des agents hydrophobes et sensibles a l'eau
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6541025B1 (en) *	1999-12-30	2003-04-01	Shear/Kershman Laboratories, Inc.	Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
SE0200154D0 (sv) *	2002-01-21	2002-01-21	Galenica Ab	New process
DE10300325A1 (de) *	2003-01-09	2004-07-22	Hexal Ag	Granulat mit öliger Substanz, Herstellungsverfahren und Tablette
CA2516448A1 (fr) *	2003-02-19	2004-09-02	H. Lundbeck A/S	Procede de preparation d'un agglomere par agglomeration a chaud

2002
- 2002-01-21 SE SE0200154A patent/SE0200154D0/xx unknown
2003
- 2003-01-21 US US10/501,899 patent/US20050084526A1/en not_active Abandoned
- 2003-01-21 WO PCT/SE2003/000093 patent/WO2003061630A1/fr not_active Ceased
- 2003-01-21 WO PCT/SE2003/000092 patent/WO2003061627A1/fr not_active Ceased
- 2003-01-21 US US10/501,873 patent/US7422757B2/en not_active Expired - Lifetime
- 2003-01-21 EP EP03701205A patent/EP1467708A1/fr not_active Ceased
- 2003-01-21 EP EP03701206.9A patent/EP1467713B1/fr not_active Expired - Lifetime

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060182799A1 (en) *	2002-01-21	2006-08-17	Jari Alander	Tabletting process
US7422757B2 (en) *	2002-01-21	2008-09-09	Galencia Ab	Tabletting process
US12318425B2 (en)	2018-10-23	2025-06-03	Stabicon Life Sciences Pvt. Ltd.	Formulation comprising water soluble particles of a non-curcuminoid and a curcuminoid

Also Published As

Publication number	Publication date
WO2003061630A8 (fr)	2004-12-09
US20060182799A1 (en)	2006-08-17
EP1467708A1 (fr)	2004-10-20
SE0200154D0 (sv)	2002-01-21
WO2003061630A1 (fr)	2003-07-31
EP1467713A1 (fr)	2004-10-20
US7422757B2 (en)	2008-09-09
WO2003061627A1 (fr)	2003-07-31
EP1467713B1 (fr)	2014-06-04

Publication	Publication Date	Title
Kumar et al.	2010	Self emulsifying drug delivery system (SEDDS): Future aspects
DE60312333T2 (de)	2007-12-20	Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung
CA2689639C (fr)	2014-06-10	Forme posologique pharmaceutique solide
AU731176B2 (en)	2001-03-22	Improved pharmaceutical composition comprising Fenofibrate
DE69812690T2 (de)	2004-01-22	Arzneistoffverabreichungssystem auf basis von flüssigkristall-strukturen
JP6666490B2 (ja)	2020-03-13	Ｃｇｒｐ活性化合物の錠剤製剤
DK2600846T3 (en)	2016-01-11	PHARMACEUTICAL DOSAGE FORM COMPRISING 6'-fluoro- (N-methyl or N, N-dimethyl -) - 4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyrano [3 , 4, b] indole] -4-amine
US20050084526A1 (en)	2005-04-21	New process 1
US20090304795A1 (en)	2009-12-10	Tablets with improved drug substance dispersibility
JP2006511536A (ja)	2006-04-06	水貧溶性薬物のバイオアベイラビリティーを改善する自由流動性固形製剤およびその製造方法
US8703203B2 (en)	2014-04-22	Oral dosage form of deferasirox
DE602005003343T2 (de)	2008-09-11	Arzneiimittel mit verdecktem geschmack in aufbrechenden multipartikeln
JP2004536108A (ja)	2004-12-02	アセクロフェナックを含有する経済的な経口用製剤の組成及び製法
WO2022013360A1 (fr)	2022-01-20	Composition pharmaceutique comprenant un ivacaftor
EP3569225A1 (fr)	2019-11-20	Dispersion solide contenant du ritonavir
KR20040006887A (ko)	2004-01-24	아세트아미노펜을 함유하는 제어방출성의 경구용 제제
NZ530473A (en)	2006-02-24	Granulates containing liposoluble substances and a process for the preparation thereof
KR890000182B1 (ko)	1989-03-09	액상 윤활제-함유 약제학적 조성물 및 약제학적 제형의 용해도 개선방법
CA2273272C (fr)	2004-09-21	Formes galeniques pour l'administration de medicaments a liberation immediate
KR20010034313A (ko)	2001-04-25	부작용이 감소된 서방성 티아가빈 제형
US20060141044A1 (en)	2006-06-29	Pharmaceutical compositions based on diclofenac derivate

Legal Events

Date	Code	Title	Description
2005-01-10	AS	Assignment	Owner name: GALENCIA AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALANDER, JARI;NORBERG, STAFFAN;HANSSON, HENDRI;AND OTHERS;REEL/FRAME:016139/0797 Effective date: 20040709
2008-11-24	STCB	Information on status: application discontinuation	Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

Date

Code

Title

Description

2005-01-10

Assignment

Owner name: GALENCIA AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALANDER, JARI;NORBERG, STAFFAN;HANSSON, HENDRI;AND OTHERS;REEL/FRAME:016139/0797

Effective date: 20040709

2008-11-24

STCB

Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION